Interaction Between Inorganic Nitrate Supplementation and Metformin in Individuals With Prediabetes (NO3-PreDM)
Status
Conditions
Treatments
Details and patient eligibility
About
This study is examining whether short-term supplementation with inorganic nitrate, in the form of beetroot juice, can enhance blood vessel health, insulin sensitivity, and exercise capacity in individuals with prediabetes. We will be comparing the responses in individuals who are taking metformin to those who are naive to metformin. The results from this study may help identify non-pharmacological interventions in prediabetes.
Full description
One in 10 Americans have diabetes, with ~ 95% having type 2 diabetes (T2D). Another 1 in 3 have prediabetes, with 70% developing T2D during their lifetimes. Exercise is the standard of care for T2D. However, responses to exercise are blunted in T2D, in part due to the widespread use of metformin, which may inhibit mitochondrial function. Alternative therapies, such as inorganic nitrate supplementation, may provide benefits without attenuating exercise responses.
Purpose: To examine inorganic nitrate supplementation on exercise tolerance, vascular function, and insulin sensitivity in subjects with PD (an ideal time to prevent progression to T2D) who are either taking or naïve to metformin pharmacotherapy.
This study willl recruit twenty-four individuals with PD (12 on, 12 metformin naïve) will participate in a double-blind cross-over design after either oral nitrate or placebo supplementation, including: 1) tests of vascular function (pulse wave velocity, flow mediated dilation, microvascular function with post-occlusive reactive hyperemia, local thermal heating, and skin ACh iontophoresis); 2) exercise testing to determine VO2peak and lactate threshold; 3) an oral glucose tolerance test; and 4) an exercise time trial to exhaustion.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Individuals who can communicate meaningfully with the investigator and can provide written consent.
- Confirmed prediabetic individuals (ages 18-60 years old) (2-hour glucose of 140-199 mg/dL following OGTT test or HbA1c between 5.7-6.4% tested on two occasions within 6 months).
- Taking metformin (stable dose for at least a week) or naïve to metformin
- Sedentary (<1 day/week of structured exercise)
- Be able to perform exercise on a cycle ergometer without assistance
- Stable medication regimen for the last 6 months
- If female, have a normal menstrual cycle
Exclusion criteria
- Estimated Glomerular filtration rate (GFR) ≤ 45
- Body mass index ≥ 40 Kg/m2
- HbA1c > 6.4%
- Smokers within the last 5 years
- Has experienced significant weight loss ~3 kg in the last three months or is taking any weight loss drugs
- Current medical condition that prohibits exercising at high intensities
- Currently on hormone replacement of any kind
- History of myocardial infarction, cerebrovascular event, acute or unstable disease other than pre-diabetes or obesity
- Currently taking any of the following medications (calcium channel blockers, statins, ACE or renin inhibitors, angiotensin receptor blockers, organic nitrates (e.g., nitroglycerine) or recent regular use of inorganic nitrates, alpha- or beta-blockers, diuretics, proton pump inhibitors, PDE-5 inhibitors (e.g.,: Cialis, Viagra), or xanthine oxidase inhibitors (e.g.,: Allopurinol))
- Oral antibiotic use within the previous four weeks, including over-the-counter antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use
- Oral cancer/severe oral disease
- Uncontrolled hypertension (>140/90)
- Had hysterectomy or oophorectomy
- Fetuses, neonates, children, prisoners, cognitively impaired, non-English speaking participants
Trial design
Primary purpose
Allocation
Interventional model
Masking
24 participants in 4 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
Money Ghimire, M.S
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal